MedKoo Cat#: 414673 | Name: Oxyfedrine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Oxyfedrine is a drug used in the treatment of angina pectoris, heart failure, conduction defects, and myocardial infarction. It is a partial agonist at beta adrenergic receptors and acts as a coronary vasodilator and cardiotonic agent.

Chemical Structure

Oxyfedrine
Oxyfedrine
CAS#15687-41-9

Theoretical Analysis

MedKoo Cat#: 414673

Name: Oxyfedrine

CAS#: 15687-41-9

Chemical Formula: C19H23NO3

Exact Mass: 313.1678

Molecular Weight: 313.39

Elemental Analysis: C, 72.82; H, 7.40; N, 4.47; O, 15.32

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Oxyfedrine; Oxifedrina; Oxyfedrinum
IUPAC/Chemical Name
1-Propanone, 3-((2-hydroxy-1-methyl-2-phenylethyl)amino)-1-(3-methoxyphenyl)-, (R-(R*,S*))-
InChi Key
GDYUVHBMFVMBAF-LIRRHRJNSA-N
InChi Code
InChI=1S/C19H23NO3/c1-14(19(22)15-7-4-3-5-8-15)20-12-11-18(21)16-9-6-10-17(13-16)23-2/h3-10,13-14,19-20,22H,11-12H2,1-2H3/t14-,19-/m0/s1
SMILES Code
O=C(C1=CC=CC(OC)=C1)CCN[C@@H](C)[C@H](O)C2=CC=CC=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 313.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Oxyfedrine. Lancet. 1981 Jan 3;1(8210):25-6. PMID: 6109057. 2: Otsuki Y, Yamasaki J, Suina K, Okazaki S, Koike N, Saya H, Nagano O. Vasodilator oxyfedrine inhibits aldehyde metabolism and thereby sensitizes cancer cells to xCT-targeted therapy. Cancer Sci. 2020 Jan;111(1):127-136. doi: 10.1111/cas.14224. Epub 2019 Nov 22. PMID: 31692172; PMCID: PMC6942438. 3: Hahn N, Raqué B, Holst A, Henn I, von Randow H, Malotki D, Oehr P, Felix R. Die Wirkung von Oxyfedrin auf Hämodynamik, Inotropie und Durchblutung des partiell ischämiegeschädigten Myokards nach Prämedikation mit Digoxin. Untersuchungen am narkotisierten Hund [The action of oxyfedrine on haemodynamics, inotropism and blood perfusion of the partially ischaemic myocardium after digoxin premedication. Studies on anaesthetized dogs (author's transl)]. Arzneimittelforschung. 1981;31(3):410-4. German. PMID: 7194664. 4: Sternitzke N, Schieffer H, Rettig G, Bette L. Zum Wirkmechanismus von Oxyfedrin als partieller Betarezeptorenagonist [Mechanism of action of oxyfedrine as a partial beta receptor agonist]. Z Kardiol. 1984 Sep;73(9):586-93. German. PMID: 6095552. 5: Parratt JR. The haemodynamic effects of prolonged oral administration of oxyfedrine, a partial agonist at beta-adrenoceptors: comparison with propranolol. Br J Pharmacol. 1974 May;51(1):5-13. doi: 10.1111/j.1476-5381.1974.tb09625.x. PMID: 4155336; PMCID: PMC1776796. 6: Osswald W, Branco D. The lipolytic action of oxyfedrine in the dog. Pharmacology. 1971;5(3):145-52. doi: 10.1159/000136186. PMID: 5119003. 7: Appel E, Planz G, Palm D, Grobecker H, Stratmann D, Donike M. Excretion of norephedrine by man after oral administration of oxyfedrine. Eur J Clin Pharmacol. 1975 Apr 4;8(3-4):161-6. doi: 10.1007/BF00567109. PMID: 1233214. 8: Sakai K, Shiraki Y, Hashimoto K. An analysis of the B-adrenergic action of oxyfedrine. Eur J Pharmacol. 1973 Jan;21(1):81-8. doi: 10.1016/0014-2999(73)90210-0. PMID: 4145385. 9: Wetzelsberger N, Birkel M, Fuder H, Lücker PW, Stiegler S, Scheithauer S, Thümmler D. Relative bioavailability of DL-oxyfedrine HCl after single-dose oral administration of tablets as compared to equimolar solutions. Methods Find Exp Clin Pharmacol. 1995 Apr;17(3):185-91. PMID: 8531509. 10: Mackenzie JE, Parratt JR. Effects of oxyfedrine on isolated portal vein and other smooth muscles. Br J Pharmacol. 1973 Apr;47(4):827-37. doi: 10.1111/j.1476-5381.1973.tb08210.x. PMID: 4146743; PMCID: PMC1776074.